# A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Study · id `cardio:ct-nct05362058` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05362058](<https://clinicaltrials.gov/study/NCT05362058>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05362058

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 928 participants.

## Technical summary

Registry record NCT05362058. Randomized; no masking; primary purpose treatment. Start 2022-06-03 (actual); primary completion 2024-04-10 (actual). Results posted on 2025-05-16.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 928 participants (enrolled count; ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Started: 2022-06-03 (actual) (ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Primary completion: 2024-04-10 (actual) (ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Completion: 2024-04-10 (actual) (ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Results first posted: 2025-05-16 (ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Countries: United States; Brazil; Canada; China; Czechia; Germany; Greece; Japan; Mexico; Puerto Rico; South Korea (ClinicalTrials.gov record NCT05362058, source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05362058-2025-05-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
- Acronym: QWINT-2
- Condition: Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin Efsitora Alfa
- Intervention (Drug): Insulin Degludec
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment (`cardio:pubmed-39254740`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d19f70d68f684b7950e5d13da53747a61f44076c5f5282c53655706e8d8021a4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
